Advertisement

Topics

Latest "Sobi" News Stories

09:01 EST 17th January 2019 | BioPortfolio

Here are the most relevant search results for "Sobi" found in our extensive news archives from over 250 global news sources.

More Information about Sobi on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Sobi for you to read. Along with our medical data and news we also list Sobi Clinical Trials, which are updated daily. BioPortfolio also has a large database of Sobi Companies for you to search.

Showing "Sobi" News Articles 1–25 of 83

Relevant

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orphan Biovitrum AB (publ) (Sobi). Sobi will commercialise Synagis in the US and around 130 AstraZeneca employees will transfer to Sobi as part of the transaction.


AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

AZ continues sell-off, SOBI spies US expansion

AstraZeneca Sells Synagis Rights to Sobi

Anglo-Swedish drugmaker AstraZeneca has sold US right for its Synagis infant respiratory drug to Swedish Orphan Biovitrum (Sobi) for an upfront sum of $1.5 billion. The payment consists of $1 billion in cash and $500 million in Sobi ordinary shares, equivalent to a stake in the Swedish company of 8%.


Sobi tar klivet in bland större läkemedelsbolag

Sobi meddelade i mitten av november att man köper rättigheterna till ett läkemedel från Astra- Zeneca med den största marknadsandelen i USA.

Sobi gains exclusive US rights to AZ's Synagis; deal value tops $2.3bn

AstraZeneca PLC sold Swedish Orphan Biovitrum AB (Sobi) exclusive rights to commercialize the respiratory syncytial virus the...

Sobi's Recently Acquired Gamifant Gets FDA Approval for Ultra-Rare Disease

Sweden-based Sobi and Swiss-based Novimmune announced the U.S. approval of Gamifant (emapalumab-lzsg) to treat an ultra-rare disease in adults and children. Sobi’s U.S. offices are in Waltham, Mass.

Sobi's Recently-Acquired Gamifant Gets FDA Approval for Ultra-Rare Disease

Sweden-based Sobi and Swiss-based Novimmune announced the U.S. approval of Gamifant (emapalumab-lzsg) to treat an ultra-rare disease in adults and children. Sobi’s U.S. offices are in Waltham, Mass.

AstraZeneca sells lung med to Sobi for $1.5 billlion

The company will gain an 8 percent ownership stake in Sobi with the deal's total value reaching $2.3 billion when including deferred and contingency payments

AstraZeneca sells off paediatric lung infection drug to Sobi for $1.5bn

AstraZeneca has jettisoned another non-essential asset with the sale of Synagis (palivizumab), a preventative treatment for infections relating to respiratory syncytial virus (RSV), to Swedish rare disease specialist Sobi in a deal worth $1.5 billion. As part of the agreement, AZ will pay an upfront sum of $1 billion in cash and $500 million in newly issued Sobi shares, with deferred and contingen...

Sobi’s Gamifant obtains FDA approval to treat Primary HLH

Sobi and Novimmune have secured approval from the US Food and Drug Administration (FDA) for Gamifant (emapalumab-lzsg), the first and...Read More... The post Sobi’s Gamifant obtains FDA approval to treat Primary HLH appeared first on Pharmaceutical Technology.

Sobi snags rights to AstraZeneca drugs in another immunology play

"Immunology now becomes the second leg to Sobi and it helps us to articulate what specialty care is about," the company's CEO said on the deal.

Sobi to buy US rights to AstraZeneca’s Synagis drug for $1.5bn

Swedish biopharmaceutical firm Swedish Orphan Biovitrum (Sobi) has signed agreements to acquire the rights to AstraZeneca’s Synagis (palivizumab) medicine in...Read More... The post Sobi to buy US rights to AstraZeneca’s Synagis drug for $1.5bn appeared first on Pharmaceutical Technology.

Sobi to acquire Synagis US rights from AstraZeneca

Synagis, the only approved respiratory syncytial virus prophylaxis for high-risk infants, complements Sobi s expertise in paediatrics and immunology

Jefferies Healthcare Conference 2018: SOBI bets on the haemophilia market

In 2006, Swedish Orphan Biovitrum (SOBI) partnered with Bioverativ to develop a new generation of haemophilia treatments. Their leading treatments,...Read More... The post Jefferies Healthcare Conference 2018: SOBI bets on the haemophilia market appeared first on Pharmaceutical Technology.

Sobi secures NHS reimbursement for Ravicti

Rare disease group Swedish Orphan Biovitrum (Sobi) says it has gained NHS England reimbursement for Ravicti for long-term management of urea-cycle disorders (UCDs) in adults and children.

Sobi, Novimmune announce US FDA approves Gamifant to treat primary HLH

Swedish Orphan Biovitrum AB (Sobi), an international biopharmaceutical company dedicated to rare diseases, and Novimmune SA, a Swiss biotech company, announced that the US Food and Drug Administration (FDA)

AstraZeneca to Divest U.S. Synagis Rights to Sobi

NewsAstraZeneca sells U.S. rights to RSV therapy Synagis to Sobi for $1.5 billion upfront. Contributed Author: 

November’s top stories

Sobi to buy US rights to AstraZeneca’s Synagis drug for $1.5bn Swedish biopharmaceutical firm Swedish Orphan Biovitrum (Sobi) signed agreements...Read More... The post November’s top stories appeared first on Pharmaceutical Technology.

AstraZeneca sells US rights to RSV therapy Synagis to Sobi for $1.5 billion upfront https://www.firstwordpharma.com/node/1603969  $AZN $SOBI

AstraZeneca sells US rights to RSV therapy Synagis to Sobi for $1.5 billion upfront https://www.firstwordpharma.com/node/1603969  $AZN $SOBI

FDA approves Sobi's Gamifant for rare, fatal childhood disease

The FDA has approved Sobi's Gamifant, a treatment for primary hemophagocytic lymphohistiocytosis (HLH). The extremely rare condition usually manifests within the first year of life, progresses quickly and is usually fatal, with a median survival o...

Sobi licenses HLH candidate emapalumab from Novimmune

Novimmune SA granted Swedish Orphan Biovitrum AB (Sobi) exclusive global rights to emapalumab, an interferon gamma antagonist...

AZ sells rights to RSV virus drug to Sobi for $1.5bn

AstraZeneca has agreed to sell the rights to its drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) for an upfront $1.5 billion in cash and shares, plus certain conditional payments. Synagis treats serious lower respiratory tract infect...

Sobi launches Kineret for AOSD, SJIA

Sobi UK and Ireland has announced the launch of Kineret across the country offering a new treatment option for Adult Onset Stills Disease (AOSD) and Systemic-Onset Juvenile Idiopathic Arthritis (SJIA).

2018 PharmaVOICE 100 – Rami Levin, President, North America, Sobi

In this blog post, we’ll share some highlights about Rami Levin, and see some of the reasons why he was honored in this year’s PharmaVOICE 100. You can also read his full profile here. Since being named president of Sobi North America in 2014, Rami Levin has built the company into a team of nearly […] The post 2018 PharmaVOICE 100 – Rami Levin, President, North America, Sob...

Sobi Buys Synagis U.S. Rights, Half Share of MEDI18897 U.S. Profits from AstraZeneca

Swedish Orphan Biovitrum (Sobi™) has agreed to acquire U.S. rights to the marketed drug Synagis® (palivizumab) from AstraZeneca, and receive the pharma giant’s half-share of future U.S. profits and losses for the vaccine candidate MEDI8897, for $1.5 billion in cash and stock, plus potential milestone payments. Both Synagis and MEDI18897 are indicated for preventing serious […] The post ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks